In short. Treat the course as a plan with a defined end. Why sessions are never crowded, and why stopping early leaves an effect that cannot be reversed.

Key points

  • How many sessions, over how many months, which areas at which visit, when the review happens, and what would make the plan stop.
  • A course described only as a few appointments, with the end left open, is being sold rather than planned, and the difference shows in how easily those questions are answered.

A course of this substance is a plan across months rather than a set of appointments, and the parts of the plan that matter are decided at the assessment. Three of them shape the outcome more than the rest: how many sessions there are, how far apart they sit, and where the course stops.

How many sessions, and why the number is a range

The number depends on the areas treated, how much change is wanted and how your tissue responds to the first session. That last factor cannot be known in advance, which is why a plan is usually expressed as a range rather than a fixed count. What should not be a range is the endpoint. A course with no stated end and no review point is not a plan, and it is the arrangement under which patients accumulate sessions they would not have chosen.

Why the intervals are wide

The spacing is not administrative. The tissue needs time to respond to what has been placed before more is added, and the response is not visible for weeks. Sessions crowded together add to the risk of firm areas without adding to the result, because the material from the previous session is still being integrated. This is also why the intervals are not negotiable for convenience, and why a practice that offers to compress a course has misunderstood which part of it produces the effect.

What a plan should state out loud

How many sessions, over how many months, which areas at which visit, when the review happens, and what would make the plan stop. A course described only as a few appointments, with the end left open, is being sold rather than planned, and the difference shows in how easily those questions are answered.

The first session as a test

The opening session is usually deliberately conservative. It tests tolerance, placement and how your tissue responds before anything substantial is committed to an area that will not give material back. That is why the first session often produces nothing visible, and why judging the course on it is a mistake in both directions: the flat period is expected, and the absence of a result at that point says nothing about what will develop.

Signs the plan has no stopping point

  • Sessions are booked in advance without a review of what the last one produced.
  • The number of sessions is described as however many it takes, with no endpoint agreed.
  • More material is proposed before the tissue has finished responding to what is already there.

The honest framing is that a course is a commitment to a sequence whose end is defined at the start. A patient who knows how many sessions, across how many months, judged at which point and stopped on what evidence has the information the decision requires. A patient told only that a few sessions will be needed has been given the least useful version of the plan, and the one hardest to stop.

Related reading

Frequently asked questions

Why can the sessions not be scheduled closer together?

Because the tissue is still responding to what has already been placed, and the response is invisible for weeks. Crowding sessions adds to the risk of firm areas without producing more of the effect, and there is no dissolving agent if the area ends up over-treated.

What should the end of the course look like?

A defined number of sessions with a stated review point rather than an open series. The decision to add more should be based on standardised photographs and on whether the change is still developing, not on a schedule or on how the patient feels that month.

What happens to the plan if I stop after two sessions?

You keep whatever has developed and there is no way to remove it, while the result is incomplete. The material already placed continues to behave as it would have. Stopping is a legitimate decision, and it is not a reversal of the sessions already given.

Risks & Limitations

  • Irreversibility: there is no agent that reverses this substance. An uneven or unwanted result is managed over time, with injected treatment, or occasionally by removal, and never switched off.
  • Nodules and granulomas — firm lumps or an inflammatory reaction that can appear weeks or months after treatment, most often in the window when the result is being judged.
  • Unevenness or over-correction, which is harder to correct than under-treatment in an area that cannot be dissolved.
  • Nothing is visible on the day and the treated area may look unchanged for several weeks. This is expected rather than a sign the treatment has failed.
  • Infection or inflammation at an injection site, which needs prompt assessment rather than waiting.
  • Tenderness, swelling, occasional bruising and occasional headache after treatment.
  • The result develops over months, cannot be judged before six months, is not permanent, and declines gradually after its fullest point; the face continues to age.

When to Seek Care

  • A firm, growing or painful lump at or near an injection site, appearing weeks or months after treatment — this needs assessment even when it is not painful.
  • Redness, warmth, swelling or pus at an injection site, or fever.
  • Skin breakdown, blistering, or a dusky or mottled patch over a treated area — seek care immediately.
  • Increasing pain, or pain out of proportion to the injection.
  • Difficulty breathing, facial swelling or a widespread rash — possible severe reaction; seek emergency care immediately.

References & Further Reading

  • American Academy of Dermatology (AAD) — injectable and skin safety information
  • American Society of Plastic Surgeons (ASPS) — injectable treatment guidance
  • U.S. Food and Drug Administration (FDA) — approved injectable products and safety communications
  • National Medical Products Administration (NMPA, China) — approved product status
  • Chongqing West District Hospital — Plastic Surgery & Aesthetics Medical Center

Medically reviewed by Ke He, MD (何锞), Deputy Director & Head of Skin & Laser Aesthetics. Last reviewed: 19 September 2026.

This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.